1. PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer
- Author
-
Andrä Brunner, Aldwin Suryo Rahmanto, Henrik Johansson, Marcela Franco, Johanna Viiliäinen, Mohiuddin Gazi, Oliver Frings, Erik Fredlund, Charles Spruck, Janne Lehtiö, Juha K Rantala, Lars-Gunnar Larsson, and Olle Sangfelt
- Subjects
PTEN ,DNA-PK ,AZD1775 ,basal-like breast cancer ,WEE1 ,cyclin E ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Inhibition of WEE1 kinase by AZD1775 has shown promising results in clinical cancer trials, but markers predicting AZD1775 response are lacking. Here we analysed AZD1775 response in a panel of human breast cancer (BC) cell lines by global proteome/transcriptome profiling and identified two groups of basal-like BC (BLBCs): ‘PTEN low’ BLBCs were highly sensitive to AZD1775 and failed to recover following removal of AZD1775, while ‘PTEN high’ BLBCs recovered. AZD1775 induced phosphorylation of DNA-PK, protecting cells from replication-associated DNA damage and promoting cellular recovery. Deletion of DNA-PK or PTEN, or inhibition of DNA-PK sensitized recovering BLBCs to AZD1775 by abrogating replication arrest, allowing replication despite DNA damage. This was linked to reduced CHK1 activation, increased cyclin E levels and apoptosis. In conclusion, we identified PTEN and DNA-PK as essential regulators of replication checkpoint arrest in response to AZD1775 and defined PTEN as a promising biomarker for efficient WEE1 cancer therapy.
- Published
- 2020
- Full Text
- View/download PDF